Amphastar Pharmaceuticals, Inc. (AMPH) EPS Estimated At $-0.04

March 11, 2018 - By Vivian Currie

 Amphastar Pharmaceuticals, Inc. (AMPH) EPS Estimated At $ 0.04
Investors sentiment increased to 0.91 in 2017 Q3. Its up 0.15, from 0.76 in 2017Q2. It increased, as 11 investors sold Amphastar Pharmaceuticals, Inc. shares while 32 reduced holdings. 10 funds opened positions while 29 raised stakes. 20.04 million shares or 0.68% less from 20.18 million shares in 2017Q2 were reported.
Raymond James & Associate has 26,218 shares. Group accumulated 28,649 shares. Ubs Asset Mgmt Americas owns 0.01% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 471,344 shares. Northern Trust Corp has invested 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Millennium Mngmt Ltd holds 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 15,901 shares. Dekabank Deutsche Girozentrale has 24,600 shares for 0% of their portfolio. 12,380 were accumulated by Capital One Association. State Of Wisconsin Inv Board holds 28,000 shares or 0% of its portfolio. Legal And General Gp Public Ltd stated it has 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Dimensional Fund Advsr L P invested in 1.56M shares or 0.01% of the stock. Cornerstone Cap Management Holdg reported 283,200 shares. Ameriprise Fincl holds 0% or 184,260 shares. State Of Tennessee Treasury Department reported 0% of its portfolio in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Sg Americas owns 16,385 shares for 0% of their portfolio. Pinebridge Invs L P holds 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) or 4,414 shares.

Analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report $-0.04 EPS on March, 12.They anticipate $0.02 EPS change or 33.33 % from last quarter’s $-0.06 EPS. After having $0.07 EPS previously, Amphastar Pharmaceuticals, Inc.’s analysts see -157.14 % EPS growth. The stock increased 1.81% or $0.34 during the last trading session, reaching $19.14. About 300,314 shares traded or 58.95% up from the average. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has risen 8.19% since March 11, 2017 and is uptrending. It has underperformed by 8.51% the S&P500.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Ratings Coverage

Among 6 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Amphastar Pharmaceuticals had 26 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, February 19 by Wells Fargo. The firm has “Buy” rating by Jefferies given on Thursday, November 9. Needham maintained it with “Buy” rating and $20 target in Tuesday, May 10 report. The stock has “Outperform” rating by Raymond James on Tuesday, March 14. The firm earned “Hold” rating on Thursday, November 9 by Raymond James. The rating was maintained by Needham with “Buy” on Friday, December 1. The rating was maintained by Piper Jaffray on Friday, October 20 with “Buy”. The stock of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has “Market Perform” rating given on Friday, November 10 by BMO Capital Markets. The firm has “Buy” rating given on Friday, October 27 by Jefferies. Needham maintained the stock with “Buy” rating in Tuesday, September 26 report.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $879.98 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

More important recent Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news were published by: which released: “US jury sides with Amphastar over Momenta in drug patent trial” on July 21, 2017, also published article titled: “Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold …”, published: “Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended …” on May 08, 2017. More interesting news about Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was released by: and their article: “Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold …” with publication date: March 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: